Long-term follow-up of people with sickle cell disease treated with gene therapy
Follows people with sickle cell disease who received gene therapy, for 15 years.
Key facts
- Who runs it
- Genetix Biotherapeutics Inc.
- Where
- Atlanta, Bethesda, Birmingham, Chapel Hill, Charleston, Chicago, Durham, Hackensack, Houston, Minneapolis, New Hyde Park, New York, Oakland, Philadelphia, and Richmond, United StatesSee the 15 sitesAlso in 1 other country, 1 site
- Registry title
- Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy
- Status
- Enrolling by invitation
- Phase
- Phase 3
- People taking part
- 85 people, planned
- Started
- 21 Oct 2020
- Expected to end
- Jan 2038
- Type of study
- Observational
- Treatments tested
- Safety and efficacy assessments
- Record updated
- 20 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with sickle cell disease who already received gene therapy in a bluebird bio-sponsored study. They are followed for a total of 15 years after the infusion.
- Age
- 2 Years to 53 Years
- Sex
- All sexes can join.
- Earlier treatment
- Must have been treated with the gene therapy drug product for sickle cell disease in a bluebird bio-sponsored clinical study.
Main reasons for not taking part
- The record lists no exclusion criteria.
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Provision of written informed consent for this study by subject, or as applicable, subject's parent(s)/legal guardian(s)
- Treated with drug product for therapy of sickle cell disease in a bluebird bio-sponsored clinical study
Who cannot take part
- There are no exclusion criteria for this study
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 2 and 53 years old?
Where in United States
Also in 1 other country, 1 site
- Children's Healthcare of AtlantaAtlanta, United StatesEnrolling by invitation
- Warren Grant Magnuson Clinical CenterBethesda, United StatesEnrolling by invitation
- University of AlabamaBirmingham, United StatesEnrolling by invitation
- The University of North CarolinaChapel Hill, United StatesEnrolling by invitation
- Medical University of South CarolinaCharleston, United StatesEnrolling by invitation
- Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, United StatesEnrolling by invitation
- Duke University Medical CenterDurham, United StatesEnrolling by invitation
- Hackensack University Medical CenterHackensack, United StatesEnrolling by invitation
- Baylor College of MedicineHouston, United StatesEnrolling by invitation
- University of Minnesota/Masonic Children's HospitalMinneapolis, United StatesEnrolling by invitation
- Cohen Children's Medical CenterNew Hyde Park, United StatesEnrolling by invitation
- Columbia University Medical CenterNew York, United StatesEnrolling by invitation
- UCSF Benioff Children's Hospital OaklandOakland, United StatesEnrolling by invitation
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesEnrolling by invitation
- Virginia Commonwealth UniversityRichmond, United StatesEnrolling by invitation
About the trial
What the trial wants to find out
This is a multi-center, long-term safety and efficacy follow-up study for subjects with sickle cell disease who have been treated with ex vivo gene therapy drug product in bluebird bio-sponsored clinical studies. After completing the parent clinical study (approximately 2 years), eligible subjects will be followed for an additional 13 years for a total of 15 years post-drug product infusion. No investigational drug product will be administered in the study.
The group in the trial
- Subjects with sickle-cell disease
Subjects treated with ex vivo gene therapy drug product for sickle cell disease in a bluebird bio-sponsored study who agree to participate in this long-term follow-up study
Treatment: Safety and efficacy assessments
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Long-term Follow-up of Subjects with Sickle Cell Disease Treated with Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced with a Lentiviral Vector
- Plain-language title
- Long-term follow-up of people with sickle cell disease treated with gene therapyGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT04628585, who can take part
- Publications
- Record updated
- 20 March 2025